InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$690.00

2026-10-16

Market Cap

$255.1B

Volume

2.1M

52-Wk High

$704.00

52-Wk Low

$435.27

Trailing PE

37.1

P/S

5.51

Gross Margin

41.0%

Net Margin

15.1%

ROE

13%

ROIC

8%

Piotroski

6/9

Altman Z

4.0

1-Yr Return

+28.7%

5-Yr Return

+154.1%

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.

SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNYSEMarket Cap$255.1BEmployees125,000 (SEC-filed)CEOMarc N. CasperIPO1980-03-17CountryUS

168 Third Avenue, Waltham, MA 02451 · Tel 781 622 1000 · thermofisher.com

INSIDERSTREET SCORE63 / 100Street mean $689.00 (12 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$63M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · TMO +28.7% · S&P 500 +15.9% · spread +12.8pp

7 Years vs S&P 500 · TMO +154.1% · S&P 500 +189.9% · spread -35.8pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE63of 100

Score Breakdown

Profitability	52/100
Growth	49/100
Momentum	78/100
Quality	75/100
Earnings Quality	76/100
Balance Sheet	49/100
Value	49/100
Risk (safety)	80/100
Overall	62.7/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
DHR	65
NTRA	50
A	71
IDXX	80
IQV	56
WAT	47
TMO	63

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 63 in 24 Q2, latest 63 — -1 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY63 / 100IS Score 62.7 / 100 · -0.7 from peak of 63

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 88 / 100 · Power +75 · 21 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 63 and price structure at 88 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 62.7	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 58 → 57 → 58 → 63	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 2,712 → now 2,634	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)3 buys2026-08-07

Insider Buys (180d)0none disclosed

ETF Funds (30d)1415 up / 1193 downnet +222 funds

Institutions Added (13F)24managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 2,712 · latest 2,634 (-78 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	2,634	339.1M	$166.6B	91.4%
2026 Q1	2,610	332.3M	$159.7B	89.6%
2025 Q4	2,712	375.0M	$191.7B	101.1%	ex-outlier 91.9%
2025 Q3	2,516	331.9M	$155.9B	89.5%
2025 Q2	2,465	336.4M	$131.4B	90.7%
2025 Q1	2,580	339.6M	$160.2B	91.5%
2024 Q4	2,625	338.9M	$166.1B	91.3%
2024 Q3	2,581	338.8M	$196.8B	91.3%
2024 Q2	2,555	339.5M	$178.1B	91.5%
2024 Q1	2,540	338.0M	$186.4B	91.1%
2023 Q4	2,501	341.9M	$173.9B	92.2%
2023 Q3	2,375	342.1M	$165.3B	92.2%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2025-12 reads 101.09%. Institutions cannot hold more of a company than exists. The reported 375.0M shares exceed the 371.0M outstanding, and a single filer accounts for the excess: VANGUARD GROUP INC reports 34,133,702 shares against 33,845,406 the prior quarter, a 1x jump, which alone would be 9.2% of the company. Excluding that filing, ownership is 91.9%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Weisler Dion J	director	2026-09-26	A-Award	56	—	2,847
Sperling Scott M	director	2026-09-26	A-Award	63	—	17,738
Lynch Karen S	director	2026-09-26	A-Award	46	—	399
Keith R. Alexandra	director	2026-09-26	A-Award	46	—	1,378
Johnson Jennifer M	director	2026-09-26	A-Award	46	—	769
Pettiti Gianluca	President & COO	2026-08-31	SELL	3,733	$2.29M	23,216
Pettiti Gianluca	President & COO	2026-08-31	EXERCISE	3,733	$1.16M	26,949
Pettiti Gianluca	President & COO	2026-08-31	EXERCISE	3,733	$1.16M	7,467

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	126	107,308	$62.7M	Counted
M — Exercises (paired A/D)	13	86,493	$29.6M	None — mechanics
F — Tax withholding	46	14,010	$7.7M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$62.7M126 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-08-31	Pettiti Gianluca	4,133	$2.5M
2026-08-24	Casper Marc N	275	$0.2M
2026-08-21	Casper Marc N	10,000	$6.3M
2026-08-20	Casper Marc N	10,000	$6.3M
Trailing 12 mo	36 filings	337,372	$181M

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.53%	28.0M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-08-07	2026-09-07
Dan Newhouse	House	SELL	$1,001 - $15,000	2026-07-10	2026-07-20
Daniel Milton Newhouse	House	SELL	$1,001 - $15,000	2026-07-10	2026-07-20
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-21
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
Angus King	Senate	SELL	$1,001 - $15,000	2025-07-21	2025-08-18

House 12-Mo17 trades6 purchases

Senate 12-Mo2 trades2 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)2,610

13F Shares332M89.6% of shares out

New / Closed172 / 231positions, QoQ

Increased / Reduced979 / 1,099positions, QoQ

Put/Call (13F)1.05option positions

Free Float99.8%369M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Ninety One Uk Ltd	528,090	$356M
Sarasin & Partners Llp	256,996	$173M
Douglas Lane & Associates, Llc	216,638	$146M
Assenagon Asset Management S.A.	214,236	$145M
Vontobel Holding Ltd.	177,438	$120M
Perpetual Ltd	148,301	$100M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.3%	$7.9B
VSMPX	0.3%	$7.9B
VTSAX	0.3%	$7.9B
VTI	0.3%	$7.9B
VOO	0.4%	$6.6B
VFFSX	0.4%	$6.6B

13F Filers Holding TMO — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session45.7%2026-10-15

20-Day Avg44.0%50-day 47.0%

TrendFalling20d vs 50d

By Market CenterQ: 45% · N: 51% · B: 50%latest session

Weekly Notional ($B)

Where TMO Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	3.5M	32 sh
Ubsa Ubs Ats	3.0M	38 sh
Sgmt Sigma X2	2.0M	32 sh
Ebxl Level Ats	1.8M	21 sh
Mlix Instinct X	1.8M	45 sh
Bids Bids Ats	1.1M	251 sh

Where a dollar of Thermo Fisher Scientific Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$23.0B	52%
Europe	$11.8B	27%
Asia Pacific	$8.1B	18%
All Other Countries	$1.6B	4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TMO (live moat model)Peer median: DHR · NTRA · A · IDXX · IQV

Component scores from the live moat model. Peer median illustrative.

Moat score 76/100 — Wide; primary source Intangible Assets.

3.8 · Employees (SEC filings)

Officer	Title
Marc N. Casper	Chairman & CEO
James Meyer	Senior Vice President & Chief Financial Officer
Gianluca Pettiti	President, COO & President of Products and Technologies
Alan J. Malus	Senior Vice President of Strategy & Corporate Development

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)4 of 6recent quarters

Avg Surprise+3.3%

Next Report2026-10-21

Income Quality1.29OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+21.7%	+14.5%	-4.6%	+0.1%	+3.9%
Gross profit	+22.5%	-3.2%	-9.6%	+3.1%	-5.4%
Operating income	+30.7%	-17.4%	-12.7%	+2.9%	+5.8%
Net income	+21.2%	-10.0%	-13.7%	+5.7%	+6.3%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	39.2	44.9	42.9	42.9	44.6
Cost of revenue	19.6	25.9	25.7	25.2	27.8
Gross profit	19.6	19.0	17.2	17.7	16.8
R&D expense	1.4	1.5	1.3	1.4	1.4
SG&A expense	7.9	9.0	8.4	8.7	7.3
Operating income	10.3	8.5	7.4	7.7	8.1
EBITDA	12.0	11.9	11.2	11.8	11.5
D&A	2.6	3.4	3.4	3.1	2.8
Pretax income	8.8	7.7	6.2	7.0	7.3
Income tax	1.1	0.7	0.3	0.7	0.5
Net income	7.7	7.0	6.0	6.3	6.7
Diluted EPS ($)	19.46	17.64	15.45	16.53	17.74
Diluted shares (M)	397	394	388	383	377

Operating CF$8B

CapEx$2B

Free cash flow$6B

SBC$0B

Buybacks$3B

Net cash change$6B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	8.5	8.1	4.0	9.9
ST investments	0.0	0.0	1.6	0.3
Receivables (net)	9.4	9.7	9.6	10.6
Total current assets	25.2	24.6	22.1	28.7
PP&E (net)	10.9	11.0	10.8	12.0
Goodwill + intangibles	58.7	60.7	61.4	65.2
Total assets	97.2	98.7	97.3	110.3
Accounts payable	3.4	2.9	3.1	3.6
Short-term debt	5.9	3.9	2.5	3.8
Deferred revenue	2.6	2.7	2.9	2.7
Total current liabilities	17.0	14.0	13.3	15.2
Long-term debt	28.9	31.3	29.1	35.9
Total liabilities	53.0	51.9	47.7	56.8
Shareholders' equity	44.1	46.8	49.7	53.5

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	7.0	6.0	6.3	6.7
D&A	3.4	3.4	3.1	2.8
Stock-based compensation	0.3	0.3	0.3	0.0
Working capital change	(1.0)	(0.5)	(0.3)	(1.8)
Operating cash flow	9.2	8.4	8.7	7.8
Capital expenditures	(2.2)	(1.5)	(1.4)	(1.5)
Investing cash flow	(2.2)	(5.1)	(5.8)	(4.0)
Buybacks	(3.0)	(3.0)	(4.0)	(3.0)
Dividends paid	(0.5)	(0.5)	(0.6)	(0.6)
Debt issuance / (repay)	0.7	(0.2)	(2.4)	5.3
Financing cash flow	(2.8)	(3.6)	(6.8)	1.8
Free cash flow	6.9	6.9	7.3	6.3

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	20.5%	16.4%	13.2%	13.2%	13.0%	13%
ROA	9.4%	7.2%	6.1%	6.5%	6.5%	6.2%
ROIC	12.5%	10.8%	9.5%	9.0%	8.8%	7.6%
Gross margin	50.1%	42.3%	40.1%	41.3%	37.7%	41.0%
Operating margin	26.3%	19.0%	17.4%	17.9%	18.2%	18.0%
Net margin	19.7%	15.5%	14.0%	14.8%	15.1%	15.1%
EBITDA margin	30.5%	26.6%	26.1%	27.5%	25.7%	25.0%
FCF margin	17.9%	15.4%	16.2%	16.9%	14.1%	—
VALUATION
P/E	34.00	30.86	34.14	31.34	32.53	37.1
P/B	6.44	4.88	4.38	4.00	4.09	4.9
P/S	6.70	4.78	4.78	4.63	4.90	5.51
P/FCF	37.41	31.04	29.55	27.32	34.71	34.9
EV/EBITDA	24.62	20.27	20.87	19.23	21.71	25.4
EV/Revenue	7.51	5.39	5.44	5.26	5.59	6.3
Earnings yield	2.9%	3.2%	2.9%	3.2%	3.1%	2.73%
FCF yield	2.7%	3.2%	3.4%	3.7%	2.9%	2.87%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.50	1.48	1.75	1.66	1.89	1.55
Quick ratio	1.12	1.15	1.39	1.29	1.53	1.18
Debt / equity	0.89	0.82	0.78	0.66	0.76	0.81
Debt / assets	38.2%	37.1%	36.9%	33.7%	37.0%	37.6%
Net debt / EBITDA	2.66	2.31	2.54	2.32	2.68	3.33
Interest coverage	17.48	11.79	5.30	5.42	6.13	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.48	0.47	0.44	0.44	0.43	0.41
Receivables turnover	5.72	5.58	5.25	4.81	4.41	4.9
DSO (days)	64	65	70	76	83	74
DPO (days)	46	43	44	43	45	44
Cash conversion cycle	101	96	101	105	108	106
GROWTH (YoY)
Revenue growth	21.7%	14.5%	-4.6%	0.1%	3.9%	—
Net income growth	21.2%	-10.0%	-13.7%	5.7%	6.0%	—
EPS growth	21.8%	-8.9%	-12.6%	7.1%	7.7%	—
FCF growth	3.0%	-1.6%	0.2%	4.9%	-13.4%	—
PER SHARE ($)
EPS (diluted, TTM)	19.41	17.68	15.45	16.54	17.81	18.81
Book value / share	102.49	111.90	120.45	129.46	141.66	142.01
Revenue / share	98.52	114.29	110.46	111.96	118.19	124.89
FCF / share	17.64	17.59	17.85	18.97	16.69	19.73
Cash / share	11.25	21.69	20.83	14.54	26.82	10.95
SHAREHOLDER RETURN & SCORES
Buyback yield	0.8%	1.4%	1.5%	2.0%	1.4%	2.63%
Altman Z-Score	4.25	3.89	3.86	4.11	3.87	4.0
Piotroski F-Score	6	6	7	8	5	6/9
Beneish M-Score	-2.02	-2.40	-2.55	-2.64	-2.41	-2.59

Model	Score	Zone	Note
Piotroski F-Score	6 / 9	Middling
Altman Z-Score	4.0	Safe (>2.99)	Safe
Income quality	1.29	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.59	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.92
Interest burden	0.88
Operating margin	18.6%
Asset turnover	0.43×
Financial leverage	2.08×
= ROE	14%

Growth Quality (live)	Value
Revenue stability	0.82
Earnings stability	0.29
Earnings persistence	0.98
Revenue CAGR 3y	2.1%
EPS CAGR 3y	8.5%
FCF CAGR 3y	7.7%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield2.63%

Dividend Yield0.27%

Total Shareholder Return2.97%cash yield

SBC / Revenue0.2%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
DHR	$161.0B	40.5	8%	13.9%	+4.6%	6/9	+9.4%
NTRA	$56.7B	-289.3	-13%	-8.9%	+37.8%	6/9	+117.9%
A	$48.8B	34.0	21%	19.3%	+8.6%	7/9	+22.6%
IDXX	$44.1B	39.4	74%	27.8%	+12.8%	9/9	-12.1%
IQV	$43.9B	32.8	23%	5.9%	+8.2%	7/9	—
WAT	$42.9B	108.7	2%	-8.3%	+52.5%	5/9	—
ILMN	$39.6B	48.5	32%	17.9%	+4.9%	7/9	—
MTD	$32.5B	36.4	-736%	22.7%	+6.9%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

43 Analysts

Str Sell (0)Sell (0)Hold (7)Buy (36)Str Buy (0)

Mean Target (qtr)$689.0012 targets

Target vs. Price-0.1%last-quarter mean

Next Report2026-10-21street $6.40

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$47.88B	$48.11B / $47.57B	$25.14	$25.22 / $25.02	16
FY2027	$50.35B	$51.02B / $50.00B	$27.49	$29.03 / $26.45	16
FY2028	$53.52B	$55.28B / $52.66B	$30.34	$32.70 / $26.98	6

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$736.00	+6.7%	5
Last Quarter	$689.00	-0.1%	12
Last Year	$643.50	-6.7%	34
All Time	$633.46	-8.2%	83

Rolling mean of published targets vs. last close $690.00. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

3/5

ROE

4/5

ROA

5/5

Debt/Eq

1/5

P/E

2/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

TMO +28.7% vs S&P 500 +15.9% — spread +12.8pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$668.36	+21.64	+3.24%	Above
SMA 50	$636.60	+53.40	+8.39%	Above
SMA 200	$547.26	+142.74	+26.08%	Above
EMA 9	$674.21	+15.79	+2.34%	Above
EMA 21	$663.01	+26.99	+4.07%	Above
EMA 50	$634.25	+55.75	+8.79%	Above
EMA 200	$563.87	+126.13	+22.37%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +7521 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%91

Volume 20%94

Volatility 10%83

Patterns 15%50

This Week100% bullishof 11 price-based votes

4 Weeks Ago100%+0 pts since

12 Weeks Ago91%+9 pts since

ReadStabilizingweek-over-week trajectory

Price vs SMA 20$668.36

Price vs SMA 50$636.60

Price vs SMA 200$547.26

EMA 9/21 Cross674.2/663.0

SMA 50/200Golden

ADX DirectionADX 39

Supertrend$633

Parabolic SAR$637

SMA Slope1.940

RSI64.1

Stochastic K/D78/66

StochRSI K/D55/41

Williams %R-20

CCI172

TSI vs Signal21.7

CMO28.1

ROC5.41%

OBV SignalAccum

Chaikin MF0.250

MFI66

Force Index12M

Elder Ray Bull36.19

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 66

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$690.65 / $709.84 / $723.18	S1 / S2	$677.31 / $658.12
Bollinger (20,2)	$643.71 – $693.00	Squeeze	ON
52-wk range	$435.27 – $704.00	Off 52-wk high	-2.0%
ATR (14)	$18.82 (2.7%)	Historical vol	27.3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+3.1%Jan60%

-1.8%Feb45%

+0.9%Mar62%

+2.0%Apr60%

+0.6%May60%

+0.6%Jun50%

+5.2%Jul80%

-0.0%Aug55%

+0.2%Sep65%

+0.5%Oct65%

+1.5%Nov60%

+1.1%Dec55%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	TMO	S&P 500
Weekly volatility (σ, 1y)	4.56%	1.83%
Best / worst week (1y)	+10.1% / -10.8%	—
Max drawdown (5y, monthly)	-37.5%	—
1-week VaR (95%)	-7.5%	—
Beta (5y)	0.85	1.00

TMO EQUITY WEATHER (LIVE)PARTLY CLOUDY · +27

Trend+46

Momentum+44

Volume+48

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 290 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+26.9+43.9 vs industry

Trend+45.9+53.1 vs industry

Momentum+44.1+71.1 vs industry

Volume+48.1+48.1 vs industry

Reading	TMO	Medical - Diagnostics & Research n=227	Healthcare n=5,272	All US symbols n=70,435
Overall	+26.9	-17.0	-24.0	-20.5
Trend	+45.9	-7.2	-25.6	-21.3
Momentum	+44.1	-27.0	-28.5	-15.8
Volume	+48.1	+0.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Marc N. Casper Chairman, President and Chief	$79.9M	87% equity+incentive
Michel Lagarde Executive Vice President and	$8.9M	56% equity+incentive
Gianluca Pettiti Executive Vice President	$8.1M	55% equity+incentive
Stephen Williamson Senior Vice President and	$6.8M	55% equity+incentive
Frederick Lowery Executive Vice President	$6.6M	55% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	58
Social	69
Governance	59
Composite ESG	62

Composite ESG Trend

Filed	8-K contents	Items
2026-07-23	Earnings Release; Exhibits	2.02,9.01
2026-05-26	Shareholder Vote	5.07
2026-04-23	Earnings Release; Exhibits	2.02,9.01
2026-03-24	Other Events; Exhibits	8.01,9.01
2026-02-12	Entry into Material Definitive Agreement; Other Events; Financial Stat	1.01,8.01,9.01
2026-01-29	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2026-01-12	Departure/Election of Directors; Appointment of Officers	5.02
2025-12-01	Entry into Material Definitive Agreement; Other Events; Financial Stat	1.01,8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-21 to 2026-07-23
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-28 to 2026-09-26
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2026-03-27 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Thermo Fisher Scientific Inc. (TMO)

Institutions holding — 12 quarters

Thermo Fisher Scientific Inc. (TMO)

Monthly Net Insider Flow (000 shares)

Signal Summary

Thermo Fisher Scientific Inc. (TMO)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding TMO — quarterly

Institutional Put/Call — quarterly

Thermo Fisher Scientific Inc. (TMO)

Where TMO Trades in the Dark

Thermo Fisher Scientific Inc. (TMO)

3.8 · Employees (SEC filings)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Balance Sheet — Full

Cash Flow Statement — Full

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Street Price Target — Trajectory

Third-Party Composite Rating

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Family Scores (site weights)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)

Thermo Fisher Scientific Inc. (TMO)